# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Baird analyst Colleen Kusy maintains Coherus BioSciences (NASDAQ:CHRS) with a Outperform and lowers the price target from $9...
HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $12 price...
Truist Securities analyst Robyn Karnauskas maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price targe...
HC Wainwright & Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and raises the price tar...
New $38.7 million term loan with a May 2029 maturity $37.5 million royalty monetization financing based on future sales of L...
– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, le...